Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2022-09-30 Director's Dealing
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics AS – Mandatory notification of trade in connection with grant of options to CEO - with attachment
Director's Dealing Classification · 98% confidence The document text is titled "KRT-1500 Skjema for melding om transaksjoner utført av personer med ledelsesansvar ('primærinnsider') og deres nærstående" (KRT-1500 Form for reporting transactions carried out by persons discharging managerial responsibilities ('primary insiders') and their closely associated persons). This structure, detailing transactions by insiders (like the Chief Executive Officer, PER EDVARD WALDAY), including transaction type ('Erverv av aksjeopsjon' - Acquisition of stock option), volume, and date, is characteristic of mandatory regulatory filings concerning insider trading or director's dealings. Among the provided codes, 'Director's Dealing' (DIRS) is the most appropriate fit for reporting personal share transactions by company directors and executives.
2022-09-30 English
EXACT Therapeutics AS – Mandatory notification of trade in connection with grant of options to CEO - with attachment
Director's Dealing Classification · 95% confidence The document is a mandatory notification regarding a trade (specifically, the grant of share options) involving a primary insider (the CEO). This type of transaction disclosure, especially when related to executive compensation or insider dealings, falls under the category of Director's Dealing (DIRS) or potentially a general regulatory filing (RNS). Since the content explicitly details the grant of options to the CEO and references MAR Article 19 disclosure requirements, it is a specific report of insider transactions. The closest fit among the provided definitions is 'Director's Dealing' (DIRS), which covers personal share transactions by directors and executives. Although it mentions an attachment, the core content is the transaction disclosure itself, not just an announcement of a report's publication.
2022-09-30 English
EXACT Therapeutics AS – Mandatory notification of trade in connection with grant of options to CEO
Director's Dealing Classification · 98% confidence The document explicitly states it is a 'Mandatory notification of trade in connection with grant of options to CEO'. It details the grant of share options to a primary insider (CEO), the terms (vesting, exercise price), and references regulatory requirements like Regulation EU 596/2014 (MAR) article 19. This type of transaction report by a director or executive regarding their personal share holdings or options falls directly under the definition of Director's Dealing (insider trades). Therefore, the appropriate code is DIRS.
2022-09-30 English
EXACT Therapeutics AS announces interim results for first half 2022
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2022 INTERIM REPORT' and covers the 'First Half Year'. It contains comprehensive financial statements (Interim consolidated statement of profit or loss, financial position, cash flow), operational reviews, and management commentary. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2022
2022-09-22 English
EXACT Therapeutics AS announces interim results for first half 2022
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2477 characters) stating that the company has released its interim results for the first half of 2022. It explicitly directs the reader to the company's website to access the actual Interim Report. Per the 'Menu vs Meal' rule, since this is an announcement of a report rather than the report itself, it is classified as a Report Publication Announcement (RPA). H1 2022
2022-09-22 English
EXACT Therapeutics announces appointment of Dr Amir Snapir as Chief Medical Officer
Board/Management Information Classification · 99% confidence The document is a press release titled "EXACT Therapeutics announces appointment of Dr Amir Snapir as Chief Medical Officer". It details the hiring of a new senior executive (CMO) and provides background information on the appointee and the company. This content directly matches the definition for Board/Management Information.
2022-09-16 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.